Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01822496 · ClinicalTrials.gov registry record · Phase 2
Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer
A Phase 2 study, sponsored by National Cancer Institute (NCI).
- Terminated
- Registry status
- Phase 2
- Development phase
- 59
- Enrollment target
NCT01822496: Clinical Trial Phase 2 study, sponsored by National Cancer Institute (NCI).
NCT01822496 is a Phase 2 study that was terminated before completion, run by National Cancer Institute (NCI). The registered enrollment target is 59 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT01822496, a Phase 2 study, was terminated before completion, sponsored by National Cancer Institute (NCI).
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 59 participants
- Enrollment target
Study Summary
This randomized phase II trial studies how well erlotinib hydrochloride or crizotinib with chemoradiation therapy works in treating patients with stage III non-small cell lung cancer. Radiation therapy uses high energy x rays to kill tumor cells. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs used in chemotherapy, such as cisplatin, etoposide, paclitaxel, and carboplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. It is not yet known whether giving erlotinib hydrochloride is more effective than crizotinib with chemoradiation therapy in treating patients with non-small cell lung cancer.
Interventions
- DRUG Carboplatin
- DRUG Cisplatin
- RADIATION Radiation Therapy
- DRUG Crizotinib
- DRUG Erlotinib
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 59 participants |
| Start Date | 2013-11-04 |
| Est. Completion | 2018-06-04 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01822496
The ClinicalTrials.gov registry entry for NCT01822496 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 59 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Carboplatin is the first listed.
NCT01822496 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01822496 about?
NCT01822496 is a clinical study titled "Erlotinib Hydrochloride or Crizotinib and Chemoradiation Therapy in Treating Patients With Stage III Non-small Cell Lung Cancer". This randomized phase II trial studies how well erlotinib hydrochloride or crizotinib with chemoradiation therapy works in treating patients with stage III non-small cell lung cancer. Radiation therapy uses high energy x rays to kill tumor cells. Specialized radiation therapy that delivers a high do...
What is the current status of trial NCT01822496?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 59 participants. The study started on 2013-11-04. Estimated completion is 2018-06-04.
What interventions are being tested in trial NCT01822496?
The interventions under investigation include: Carboplatin (DRUG), Cisplatin (DRUG), Radiation Therapy (RADIATION), Crizotinib (DRUG), Erlotinib (DRUG).
Who is sponsoring clinical trial NCT01822496?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.